We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Ventless Device Addresses Significant Challenge of Blood Culture Contamination

By LabMedica International staff writers
Posted on 17 Feb 2023
Print article
Image: Kurin Jet marks a significant technological advance over the company’s own market-leading Kurin Lock (Photo courtesy of Kurin)
Image: Kurin Jet marks a significant technological advance over the company’s own market-leading Kurin Lock (Photo courtesy of Kurin)

Determining whether a bloodstream infection is present in patients is vital for their wellbeing as well as for the financial health of hospitals. The gold standard for identifying bacteremia is a blood culture test with millions of such tests being conducted annually to inform patient care decisions. However, contaminated blood cultures create a significant problem, as approximately one-third of all positive results are wrong, resulting in unnecessary antibiotics being administered to patients, longer hospital stays and a negative impact on larger community health issues, like antimicrobial resistance and life-threatening C. diff. infections. Now, a new ventless device with its unique design, speed, and ease of use can help hospitals address the significant challenge of blood culture contamination.

Kurin, Inc. (San Diego, CA, USA) has announced the limited commercial release of Kurin Jet, which is a significant technological advance over the company’s own market-leading Kurin Lock. Kurin’s revolutionary approach to the problem of contaminated blood culture is based on simple, intuitive designs that does not require any additional user steps. Similar to the Kurin Lock, the Kurin Jet also passively sidelines potential contaminants during blood culture collection. Both Kurin Lock and Kurin Jet offer a better and more sustainable approach than active, conventional mechanical diversion.

“We are excited to announce the introduction of Kurin Jet, a fundamentally different product that provides a new level of performance in addressing the blood culture contamination market,” said Bob Rogers, CEO of Kurin, Inc. “Although our current Kurin Lock is the market leader because of its small size and passive, user-friendly design, we have leapfrogged that technology and created a much faster device with a greater level of control for clinicians. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”

“Kurin Jet helps hospitals address the significant challenge of blood culture contamination with its unique design, speed, and ease of use. Based on its performance and feedback from those who have used Jet, we will limit the initial release, as demand will exceed initial production volumes. Full release will occur later this year,” added Rogers.

Related Links:
Kurin, Inc.

Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
Respiratory Syncytial Virus PCR Test
WizDx RSV CrystalMix PCR Kit
Liquid Urinalysis Control
Gold Supplier
CLIA Processor

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.